All posts by imreal

Health tech startup Prescribe FIT raises $4M in oversubscribed seed round; welcomes former Cardinal Health CEO to board


The Prescribe FIT mobile app, PACE (Prescribe, Assess, Connect, & Engage)

“After leaving Cardinal Health, I evaluated dozens of opportunities for what’s next,” Kaufmann said. “Prescribe FIT was among the most exciting companies I met with. Their team, culture and mission immediately impressed me.”

Remote monitoring and virtual lifestyle health startup Prescribe FIT recently closed an oversubscribed $4 million series seed round led by Tamarind Hill, a venture capital firm investing in tech-driven healthcare and supply chain companies. Prescribe FIT plans to use the funding to scale their solution in 2023 and beyond.

The orthopedic weight loss startup closed their seed round soon after welcoming several new, high-profile board members, as well as expanding coast-to-coast to states including Florida, Arizona, Hawaii, and others; a move that increased their number of prescribing providers 20-fold.

Additional fundraise participants include the Grote family—owners of Donatos Pizza and longtime Prescribe FIT investors—as well as practicing orthopedic surgeons and other notable business leaders such as Mike Kaufmann, the most recent CEO of Fortune 15 pharmaceutical and medical supply distributor Cardinal Health.

As his first venture since stepping down from his five-year tenure as CEO of Cardinal Health in August, Kaufmann will serve as an addition to Prescribe FIT’s board of directors.

“After leaving Cardinal Health, I evaluated dozens of opportunities for what’s next,” Kaufmann said. “Prescribe FIT was among the most exciting companies I met with. Their team, culture and mission immediately impressed me.”

Kaufmann will lend his over three decades of experience as a healthcare industry leader to advise on Prescribe FIT’s vision and growth strategy.

Joining Prescribe FIT’s board of advisors is Howard J. Luks, MD, renowned orthopedic surgeon and sports medicine specialist and author of the book, “Longevity…Simplified,” a practical guide to living a longer, healthier life.

“I’m thrilled to join Prescribe FIT as an advisory board member,” said Dr. Luks. “Their focus on lifestyle health is well-aligned with my own approach to care as an orthopedic surgeon. Together, we’re taking on what they call the ‘Orthobesity™’ crisis.”

“Orthobesity™,” a portmanteau of the words “orthopedic” and “obesity,” was coined by Prescribe FIT to describe the overrepresentation of individuals with obesity in the orthopedic patient population. As many as 55% of patients in any given orthopedic clinic are obese, compared to about 42% of the general population.

The strong association between obesity and orthopedic issues is what drives Prescribe FIT’s focus on lifestyle health and weight loss for orthopedic patients. With remote monitoring and health coaching, Prescribe FIT has helped patients lose an average of 5.4% of their weight in 16 weeks. 82% of patients reduced their severe pain in 30 days.

Beyond the numbers, Prescribe FIT has helped patients improve their health and regain physical abilities they thought were long gone. According to their testimonials page, patients have successfully reduced or eliminated their insulin use and others regained the ability to walk without assistance.

With the conclusion of their first series seed round, Prescribe FIT CEO and founder Brock Leonti said the company now has its sights set on future financing, with plans to further their momentum in customer acquisition and rapidly scale patient engagement.

“With the close of this round and two formidable additions to our team of experts, we’re strongly positioned to realize our plans for growth and further establish ourselves as the leading platform for orthopedic lifestyle health,” said Leonti.

About Prescribe FIT:

Prescribe FIT is a full-service remote monitoring and virtual lifestyle health solution that extends orthopedic care beyond the office to help patients improve their musculoskeletal (MSK) health at home with simple changes to nutrition, physical activity, and lifestyle. By combining innovative technology with one-on-one coaching and patient outreach, they help orthopedic practices stay connected to their patients to help them decrease weight, reduce pain, and improve mobility at home.

Share article on social media or email:

DecisionHealth partners with innoviHealth to offer an HCC calculator…


DecisionHealth, an HCPro brand, is proud to announce the launch of a new add-on option for SelectCoder: a Hierarchical Condition Category (HCC) calculator. The HCC calculator is used to calculate…

(PRWeb January 18, 2023)

Read the full story at https://www.prweb.com/releases/decisionhealth_partners_with_innovihealth_to_offer_an_hcc_calculator_add_on_to_selectcoder_the_premier_online_coding_resource/prweb18940709.htm

CellMax Life Announces Positive Results From Prospective Multisite Study of Novel Blood Test to Detect Colorectal Cancer and Pre-Cancer


The results from this study are incredibly promising, showing significant potential for this test for colorectal non-invasive cancer screening, thereby increasing our ability to prevent more cancers – Shai Friedland, MD, Stanford Medicine

CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced positive results from a multisite U.S. study that showed that its FirstSightTM blood test is highly accurate in detecting colorectal cancer, as well as advanced adenomas.

The data from this prospective study showed that CellMax’s FirstSight blood test demonstrated 92% sensitivity for colorectal cancer and 55% sensitivity for advanced adenomas at 91% specificity. This data aligns well with the 16-year follow-up of the National Polyp Study, in which investigators made the case that advanced adenomas should be a primary target of colorectal cancer screening.

“Simply put, colorectal cancer is preventable; many cases that occur could have been avoided had the right screening tests been performed in a timely manner,” said Douglas K. Rex, MD, Distinguished Professor Emeritus of Medicine at Indiana University School of Medicine, Former President of the American Society for Gastrointestinal Endoscopy and Former Chair of the U.S. Multi-Society (ACG, ASGE, AGA) Task Force on Colorectal Cancer. “In order to significantly reduce the incidence of colorectal cancer, an effective and easy screening test is critical. This is why I am very enthusiastic about this data on CellMax’s FirstSight. The study demonstrated numerically better detection of advanced adenomas than the best performing commercially available fecal tests, as well as other blood tests that are currently under development and have publicly disclosed their performance.”

The study was designed to reflect an asymptomatic average-risk U.S. screening population and consisted of 1038 samples collected from patients between the ages of 45-80 across 18 geographically dispersed sites. Of these 1038 samples, 954 were asymptomatic, average-risk screening patients without age enrichment, including 11 patients with colorectal cancer (2 stage I, 3 stage II, 6 stage III) and 93 patients with advanced adenomas. Additionally, 84 were case-control diseased patients with 65 known cases of colorectal cancer (9 stage I, 20 stage II, 22 stage III, 6 stage IV, 8 unstaged), and 19 known cases of advanced adenomas prior to resection to increase statistical power. All negative samples were collected from the average- risk screening cohort, and there were no negative case-control samples.

These results demonstrate best-in-class performance for detection of advanced neoplasia (colorectal cancer and advanced adenomas). CellMax’s FirstSight is the first blood test that is superior to stool tests in detecting advanced adenomas and colorectal cancer.

“There is a significant clinical unmet need when it comes to detecting colorectal cancer and pre-cancer,” said Shai Friedland, MD, lead principal investigator on the study and gastroenterologist at Stanford Medicine. “The results from this study are incredibly promising, showing significant potential for this test for colorectal non-invasive cancer screening, thereby increasing our ability to prevent more cancers.”

The multi-modal FirstSight blood test differs significantly from other first-generation ctDNA blood tests. It is able to detect advanced adenomas by combining signatures, not just from ctDNA but also from methylation along with rare epithelial cells shed from adenomas using the company’s proprietary circulating epithelial cells technology. These are all combined into a proprietary algorithm that also captures interaction between these selective biomarkers.

“There are too many unnecessary deaths from colorectal cancer,” said Atul Sharan, co-founder and CEO of CellMax Life. “Our mission with FirstSight is to find precancerous adenomas that have a high likelihood of progression to cancer and detect them before they develop into cancer. To that end, the study was designed and analyzed such that there can be high confidence that the results will be reproduced in a larger premarket approval study.”

Based on clinical data showing FirstSight’s ability to detect both colorectal cancer and advanced adenomas with high sensitivity, CellMax received Breakthrough Device Designation from the U.S. Food and Drug Administration in Q3 2021.

This data will be presented at ASCO Gastrointestinal Cancers Symposium, taking place on January 19-21, 2023. Details for the poster presentation include:

Poster Session C: Cancers of the Colon, Rectum, and Anus

January 21, 2023, at 6:30 AM PST

Location: Level 1, West Hall

Poster Abstract #75, Poster Board D12

Presented by Lead PI Dr. Shai Friedland of Stanford University Medical Center Gastroenterology and Hepatology

CellMax plans to begin a premarket approval study, with an intermediate endpoint for advanced adenoma due to their higher prevalence relative to cancer and an end-of-study endpoint of advanced adenoma plus colorectal cancer (advanced neoplasia) test that provides increased level of evidence to cancer detection due to lower prevalence. If approved, FirstSight blood test will help increase routine screening compliance for patients who are reluctant to undergo a colonoscopy or stool testing and may help prevent colorectal cancer by detecting the disease at the advanced adenoma stage.

About CellMax Life

CellMax Life is a diagnostics company focused on cancer screening with proprietary technology for detecting precancerous and cancer cells and genomic aberrations in a single blood sample. CellMax Life is headquartered in Sunnyvale, California, and has an accredited laboratory at this location. For more information, visit http://www.cellmaxlife.com.

Media Contact:

Leonard Fontes III

Cellmaxlife@antennagroup.com

(201) 874-6317

Share article on social media or email:

Continued Emotet Attacks Highlight 2023 Malware Dangers


Emotet Attacks

In January 2021 the FBI partnered with global law enforcement agencies and private companies to take down the Emotet malware. However, just eleven months later, Emotet continues to attack and evolve, emphasizing the need for organizations to prioritize cyber security in the new year.

A NYC area cyber security consultant and managed services provider (MSP) considers a recent wave of Emotet attacks in a new article. The informative article first confirms the return of the dangerous malware 11 months after law enforcement and cyber security experts from around the world celebrated its demise.

Describing it as the Botnet that refuses to die, the author describes how Emotet attacks work by using phishing campaigns to trick organizations into infecting themselves with malicious software. He then offers steps to mitigate the dangers of Emotet attacks, including disabling Microsoft Office macros, updating email filters, and security awareness training.

“In January 2021 the FBI partnered with global law enforcement agencies and private companies to take down the Emotet malware,” stated Almi Dumi, CISO, eMazzanti Technologies. “However, just eleven months later, Emotet continues to attack and evolve, emphasizing the need for organizations to prioritize cyber security in the new year.”

Below are a few excerpts from the article, “Continued Emotet Attacks Highlight 2023 Malware Dangers.”

The Botnet that Refuses to Die

“Emotet first emerged in 2014 as a simple banking trojan. Since then, it has evolved into one of the most dangerous botnet operations in the threat landscape. Two years ago, a combined effort of law enforcement and cyber security experts from around the world celebrated its demise. But Emotet re-appeared after months, stronger than ever.”

“Emotet attacks use phishing campaigns to trick organizations into infecting themselves with malicious software. Typically, the phishing emails include attached Microsoft files that contain dangerous macros. When executed, the macros spread the Emotet infection throughout a network of connected devices, creating a robot network or botnet.”

Steps to Mitigate the Danger of Emotet Attacks

“Organizations should take deliberate steps to reduce the risk of a successful attack. For instance, since Emotet typically uses macros in attached Microsoft Office files, companies should consider disabling macros unless they are signed.”

“Additionally, Emotet and other malware families commonly use email as a delivery device. Consequently, organizations should periodically review and update their email filters. And they should conduct regular security awareness training and phishing simulations. End users may prove the most important defense.”

Strengthen Cyber Defenses with Expert Help

Organizations cannot afford to leave critical digital assets under-protected. At the same time, the economic downturn and the cyber security skills gap make it difficult for companies to mount an effective defense. Partnering with cyber security experts can help.

eMazzanti Technologies provides a full range of cyber security services, from risk assessments and penetration testing to continuous monitoring and email defense. The company’s consultants work with organizations to tailor a security strategy to various needs and budgets.

Have you read?

eMazzanti Technologies Earns Modern Work Microsoft Designation to Help Customers Boost Productivity and Navigate Hybrid Work

Outsource Cyber Security for a Safe 2023

About eMazzanti Technologies

eMazzanti’s team of trained, certified IT experts rapidly deliver increased revenue growth, data security and productivity for clients ranging from law firms to high-end global retailers, expertly providing advanced retail and payment technology, digital marketing services, cloud and mobile solutions, multi-site implementations, 24×7 outsourced network management, remote monitoring, and support.

eMazzanti has made the Inc. 5000 list 9X, is a 4X Microsoft Partner of the Year, the #1 ranked NYC area MSP, NJ Business of the Year and 5X WatchGuard Partner of the Year! Contact: 1-866-362-9926, info@emazzanti.net or http://www.emazzanti.net Twitter: @emazzanti Facebook: Facebook.com/emazzantitechnologies.

Share article on social media or email:

The Top 25 Healthcare Technology Leaders of Virginia for 2023


The Healthcare Technology Report is pleased to announce The Top 25 Healthcare Technology Leaders of Virginia for 2023. While other East Coast hot spots like New York, Boston, and DC may get more attention when it comes to their healthcare technology markets, Virginia is by no means a slouch. The state is home to a number of incredibly innovative healthtech companies across a range of specialties, from pharmaceuticals to biologics, diagnostics, and medical devices, among many others. The leaders on this year’s list earned their spots thanks to their dedication to revolutionizing the industry within their specialties, delivering technologies that have the ability to transform the lives of patients and the work of clinicians.

Some of the distinguished leaders on this year’s list include Ashley Pleasants, Vice President Project Management at Elligo Health Research, whose services are dramatically accelerating the development of new pharmaceutical, biotechnology, and medical device and diagnostic products. Meanwhile, Chief Scientist David Gerdt’s CareTaker Medical has developed VitalStream, the world’s most innovative, FDA-cleared wearable vital signs monitor and early warning device. And Co-Founder and CEO Rust Felix’s Slope has developed the online eClinical Supply Chain Management (eCSCM) platform, which reduces clinical trial risks, reigns in costs, and improves the productivity of clinical trial collaborators.

This year’s awardees lead from a variety of positions, from CEO to CFO, VP, COO, and CTO. What they have in common is their demonstrated commitment to innovating in the healthcare technology space, prioritizing patient well-being in the Virginia area and around the world. Please join us in celebrating The Top 25 Healthcare Technology Leaders of Virginia for 2023.

Chris Senanayake (TCG GreenChem, Inc.), Douglas Boothe (Akorn), Keith Sullivan (Neuronetics), Ashley Pleasants (Elligo Health Research), Gregory Forton (ATCC), David Gerdt (CareTaker Medical), Rust Felix (Slope), Marjorie Zettler (Regor Pharmaceuticals Inc.), Brian Mills (Vista Clinical Diagnostics), April Hall (Biomere), Paul Bishop (Atlantic Research Group), Nathaniel Wuertz (Orthosnap), Hunter Walker (Atlantic Research Group), Ronald Gunn (Kaléo), Mike Cariola (Bode Technology), Libby Lynes (BioTel Heart), Jeff Conroy (Embody), Micah Cost (Pharmacy Quality Alliance), Jennifer Brearey (AdvaMed), Eric Edwards (Phlow Corporation), Kristina Peterman (ATCC), Juan Piacquadio (Phlow Corporation), David Voight (Acceleration Point), Kenneth Guito (Biologics Consulting), Kevin Breheny (AccuTec Blades).

The full article can be read at https://thehealthcaretechnologyreport.com/

About The Healthcare Technology Report

The Healthcare Technology Report provides market research and insights, business news, investment activity updates, and important corporate developments related to the healthcare technology sector. Based in New York City, the firm is run by a seasoned team of editors, writers, and media professionals highly knowledgeable on healthcare technology and the various companies, executives, and investors that make up the sector.

Share article on social media or email:

Genomics India Conference 2023, Feb 2nd and 3rd Bengaluru India.


Bangalore the silicon valley of India is proud to host the five star edition of biotech conference Genomics India 2023 in NIMHANS convention centre, Bangalore, on Feb 2 to 3 of 2023. This conference is being hosted by Genotypic Technology a Pioneer in Genomics since 1998. Being early movers themselves had an insight to contribute to the indian genomics landscape and have been promoting through various forums including iBioM an MSME non-profit organization for Biotech start ups.

Leaders of the Genomics world are expected to grace the occasion including Prominent figures from USA, Peru, Tanzania, UK, Israel, EU are attending. Legends in the field of Genomics are delivering lectures on cutting edge research, throwing the Genomics enterprise in open forum thru brain storming sessions, panel discussions and Q&A sessions.

The conference is co organized by QTLomics, Dhitiomics; The knowledge partner is iBioM a Biotech MSME organization nurtured by a group of Pharma-Biotech patrons in India. Biospectrum and Gubba are the press partners. A salient feature of the Conference is sheer variety of speakers from across the globe and India, delivering breakthrough innovations in Genomics in the past decades and the future to come by. M V Ramanujam Member iBioM quotes that India is well poised to explore Genome Informatics with Mathematical and Computational Prowess, as India is inherently strong in Math and Computers. This conference indeed is best suited to discuss the future of genome analytics in India, he concludes. iBioM members are offered special provisions to display their products and services at the conference.

Key round table discussions: 1- Has Genomics delivered its promise for healthcare?

2- The Regulatory environment in India for Drugs and development

3- Infectious diseases, surveillance and vaccines

The NGS analytic and Genome informatics Program runs as a satellite Program with the conference providing the scientific base and the NGS analytic session as a practical session for learning the basics of Genome informatics from QC to assembly annotation, variant calling and reporting. Certificates are provided for the Genome informatics session participants.

Special economical registration for students, Phds and postdocs available at https://genomicsindia.co.in/registration/

Share article on social media or email:

Cornerstone Prosthetics & Orthotics Provides Ukrainian Amputees with Prosthetic Care


Cornerstone patient using running blade.

Cornerstone Patient using a running blade for the first time.

Mike Smith, Partner and Practioner of Cornerstone Prosthetic & Orthotics, explains, “We look forward to continuing our collaboration with the UKRHelp Foundation on a meaningful and humanitarian mission to help Ukrainian amputees have access to prosthetic care.”

Through this partnership, UKRHelp Foundation and Cornerstone Prosthetics and Orthotics aim to bring necessary medical care to those individuals affected by the current war in Ukraine by providing prosthetics to amputees and training Ukrainians to manage long-term care for those with amputations. This partnership is critical to providing better prosthetics access to Ukraine. The ongoing conflict significantly impacts individuals’ access to basic medical and mental health support, specifically for young adults with amputations.

The UKRHelp Foundation is a non-profit organization based in Washington State that provides medical care and prosthetics to those affected by war. They are driven by a single goal – ensuring a safe future for every child, young adult, and adult living through the war in Ukraine. The Foundation works with local organizations, such as hospitals and clinics, to provide medical care, mental health support, and prosthetics to war-affected amputees. The UKRHelp Foundation also works to provide training and education to Ukrainian medical technicians on how to care for those with amputations. This includes providing education for maintaining prosthetic devices over time.

For over three decades, Cornerstone Prosthetic & Orthotics has provided Washington State residents with prosthetic and orthotic care. Cornerstone is dedicated to providing its patients with the highest quality prosthesis and orthotic devices possible to achieve their vocational, recreational, and lifestyle goals. They have an in-house fabrication department staffed by ABC Registered technicians who undergo regular continuing education to ensure they produce the most advanced prosthetic technology for their patients. An in-house fabrication department allows them to develop devices to the highest quality standards.

The UKRHelp Foundation and Cornerstone Prosthetic & Orthotics have joined forces to provide medical care, prosthetic limbs, and training for those with amputations in Ukraine. The partnership will bring patients from Ukraine to Washington State to receive rapid prosthetic devices with a quick turnaround time. With the help of this partnership, technician(s) from Ukraine will be sent to Washington State to learn how to maintain the prosthetic and provide long-term care for amputees in Ukraine.

Mike Smith, Partner, and Practioner of Cornerstone Prosthetic & Orthotics, explains, “we are looking forward to continuing our collaboration with UKRHelp Foundation on a meaningful and humanitarian mission to help amputees have access to prosthetic care. Our clinics provide treatment for people of all ages, from the youngest children to seniors. As a veteran myself, being able to care for young adults who have undergone amputation due to warfare carries tremendous significance. We recognize and respect the considerable time and attention of UKR Help, Alex, and his team, to coordinate patients’ journeys from Ukraine. Our hope is that we’ll be able to develop a longstanding relationship to continue to provide essential prosthetic support for amputees.”

With the first patients scheduled to arrive in the first quarter of 2023, the UKRHelp Foundation and Cornerstone Prosthetic & Orthotics look forward to continuing this mission to provide further aid and care to those in need in Ukraine. To learn more about UKRHelp Foundation and how to support this cause, visit https://ukrhelp.us/. To learn more about Cornerstone Prosthetics and Orthotics, visit https://www.cornerstonepo.com/.

Share article on social media or email: